Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02355 is a long intergenic non-protein coding RNA gene in humans. Long intergenic non-coding RNAs (lincRNAs) are autonomously transcribed RNAs longer than 200 nucleotides that do not overlap annotated coding genes[3]. LincRNAs can regulate chromatin remodeling, genome architecture, transcription, and RNA stability, often with tissue-specific roles and fine-tuning gene expression in certain cellular contexts[3]. Only a small fraction of lincRNAs have been well-characterized, and LINC02355 does not currently have specific functional, disease, or drug interaction data available in public databases[1][5]. Its classification is based on transcript annotation rather than protein coding, making it distinct from traditional therapeutic targets such as receptors and enzymes. If further research identifies functional roles for LINC02355 in disease or biological pathways, its status as a therapeutic target could change; however, as of now, it is not considered a druggable target.
Not applicable, as no drugs are reported to interact with LINC02355
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2355 (LINC02355).